Shire PLC recently announced that the FDA had approved a new drug product, the first skin patch to treat attention deficit hyperactivity disorder. The patch is called Daytrana, and will be available in June or July. Daytrana is recommended to be worn for nine hours. One claimed advantage of the drug patch is that doctors can more easily manage dosage and possible side effects, by having children wear it for less than the recommended daily time. In trials, the patch was shown to improve overall symptoms of ADHD. However, side effects of the drug included insomnia, weight loss, mood swings, tic, nausea, vomiting and decreased appetite.
Comments are closed.